

MITRE / FLUX NOTES **COMPASS — Metastatic Use Case v1 (w/o filters)**

DANIEL REEVES, JUHAN SONIN, 11.Jun.2019



Figma prototype is live at:

<https://www.figma.com/proto/rLpubNAfrqV99exbLVFz5c/core-cancer-pilot?node-id=2507%3A13716&viewport=-336%2C-919%2C0.2676085829734802&scaling=min-zoom>

For artboards with access to CSS snippets, go to:

<https://www.figma.com/file/rLpubNAfrqV99exbLVFz5c/core-cancer-pilot?node-id=2507%3A16365>

I

TABLE VIEW

I.I NO COMPARISON SELECTED

Treatment Options invasive ductal carcinoma of breast

There are no green comparative numbers or bars

Outcomes and criteria for 156,765 patients with Invasive ductal carcinoma of breast were collected by CancerLinQ ...[more](#)

demographic

- age: 50-59
- age at diagnosis: 41-61
- race: white
- sex: female

pathology


- T: T1c
- N: N0
- M: M0
- stage: IA
- grade: 2

biomarkers

- ER: negative
- PR: positive
- HER2: positive

genomics

- BRCA1: negative
- BRCA2: negative




I

TABLE VIEW

I.2 INTERACTIONS

Treatment Options invasive ductal carcinoma of breast

Outcomes and criteria for 156,765 patients with Invasive ductal carcinoma of breast were collected by CancerLinQ ...m



I

TABLE VIEW


I.3 COMPARISON

Treatment Options invasive ductal carcinoma of breast

Outcomes and criteria for 156,765 patients with Invasive ductal carcinoma of breast were collected by CancerLinQ ...[more](#)

The user has selected epirubicin as the treatment to be compared against. It is moved to the top row which is now styled specially.


The other rows present green/red arrows and bars to compare against the outcomes of epirubicin.



2

ICON VIEW


2.I NO COMPARISON SELECTED



2

ICON VIEW

1.2 COMPARISON SELECTED



3 SUMMARY

Overview invasive ductal carcinoma of breast

Cancer

Name	Invasive ductal carcinoma of breast
Date of diagnosis	18 Dec 2018 (age 51)
Laterality	Right
Tumor size	2.0 cm
Tumor histology	Invasive ductal adenocarcinoma
Histological grade	2 (moderately differentiated)

Staging

TNM	cT1 cN0 M0
Clinical stage	1A
Pathological stage	missing

Most recent disease status

Status	Progressing
As of	25 May 2019
Rationale	Imaging

Tumor biomarkers

Receptor Status ER	Positive
Receptor Status PR	Negative
Receptor Status HER2	Positive

Active Conditions

Condition	Diagnosed
Type 2 Diabetes Mellitus	12 Apr 2010
Hypertension	19 Oct 2008

Procedures invasive ductal carcinoma of breast